MarginsXMarginsX
Home › Markets › Health Care › LXEO

Lexeo Therapeutics Inc. (LXEO)

LXEO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.23
+12.54% on the day
Market cap
$265.0M
Micro cap
Revenue · 2022
$654K
No prior year to compare
Net income · 2022
-$59.3M
-9063.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2022-12-31, https://www.sec.gov/Archives/edgar/data/1907108/000095017024028941/0000950170-24-028941-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-12-31.

Profile

FieldValue
TickerLXEO on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO year2023
SEC CIK0001907108
SEC industry codeBiological Products, (No Diagnostic Substances)

Financials · 2022

LineValue
Revenue$654K
Net income-$59.3M
Operating income-$60.5M
Net margin-9063.8%
Operating margin-9252.1%
Revenue growthNo prior-year revenue to compare
Cash$77.3M
Total assets$97.1M
P/E (computed)Net income was not positive
P/S (computed)405.2×

Warning signs

Cash runway
12.6 months
$92.8M cash at June 30, 2026
Share count, 1 year
+51.9%
2025-08-12 to 2026-08-10 · +207.9% over 3 years
Going-concern doubt
No
10-Q filed August 12, 2026
Insider net buying, 12 months
-$985K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-12
Cash and burn$92.8M cash; operating cash flow -$22.1M a quarter.Report 2026-06-30
Shares outstanding82,046,255 (2026-08-10); 54,001,214 a year earlier; 26,645,538 three years earlier.Cover page 2026-08-10
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-10-29
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, New York, New York, United StatesPCAOB Form AP 2026-04-30
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $985K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$25.9M-$17.6M$92.8MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2026
2026-03-31
Not filed-$20.2M-$21.1M$71.8MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2025
2025-12-31
Not filed-$21.0M-$20.1M$63.0MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q3 2025
2025-09-30
Not filed-$20.3M-$29.5M$41.0MNo debt tagsNeeds four quarters10-Q 2025-11-05
Q2 2025
2025-06-30
Not filed-$26.1M-$27.2M$35.5MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q1 2025
2025-03-31
Not filed-$32.7M-$21.7M$28.9MNo debt tagsNeeds four quarters10-Q 2026-08-12
Q4 2024
2024-12-31
Not filed-$25.9M-$28.3M$35.0MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$29.5M-$17.8M$157.0MNo debt tagsNeeds four quarters10-Q 2025-11-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-10-29
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-08-12
Latest current report8-K2026-11-16
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-0.7%
1 month+4.7%
3 months-42.1%
Year to date-71.1%
1 year-68.1%
From 52-week high-73.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
OCGNOcugen Inc.$0.7730-6.62%$262.3M
SABSSAB Biotherapeutics Inc.$3.00+1.35%$270.3M
PLXProtalix BioTherapeutics Inc. (DE)$3.03-0.66%$255.5M
DTILPrecision BioSciences Inc.$7.28-3.77%$277.6M
ALLOAllogene Therapeutics Inc.$0.8070-3.78%$279.6M
AGENAgenus Inc.$6.29-6.54%$284.6M
EDITEditas Medicine Inc.$1.87-13.82%$288.6M
XFORX4 Pharmaceuticals Inc.$2.83-9.29%$289.0M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier